PharmaFluidics Accelerates Commercialization with Fresh Funding

The Column

The Column, The Column-02-12-2018, Volume 14, Issue 2
Pages: 7

PharmaFluidics has announced it has raised 7.3 million euros in its bid to expand commercialization of its novel micro-chip device.

 

PharmaFluidics has announced it has raised 7.3 million euros in its bid to expand commercialization of its novel micro-chip device.

The financing round saw fresh investment from holding company FPIM‑SFPI, as well as family offices Heran (Annie Vereecken) and RMM (Rudi Mariën). Existing investors PMV, Qbic, Theodorus, Innovatuin Fund, and Volksvermogen also reaffirmed their commitments with fresh funding.

The new funds will be used to further develop the pillar array technology platform, to expand the µPAC product range, and to scale up production and global sales.

“This funding will significantly boost our capacity to support our growth,” said Johan Devenyns, Managing Director of PharmaFluidics.

The company started shipping µPAC columns in September 2017, and have since served proteomics laboratories, medical centres, and pharmaceutical companies across Europe, the USA, and parts of Asia.

For more information, please visit www.pharmafluidics.com